via University of South Australia
University of South Australia researchers are a step closer to finding a new biomarker for osteoarthritis, a painful condition which affects more than two million Australians and costs the country an estimated $23 billion a year.
Using new state-of-the-art imaging techniques to identify signs of osteoarthritis (OA), UniSA scientists are learning more about changes at the molecular level which indicate the severity of cartilage damage.
A study led by PhD student Olivia Lee and her supervisor Associate Professor Paul Anderson using mass spectrometry imaging (MSI) has mapped complex sugars on OA cartilage, showing different sugars are associated with damaged tissue compared to healthy tissue.
The finding will potentially help overcome one of the main challenges of osteoarthritis research – identifying why cartilage degrades at different rates in the body.
“Despite its prevalence in the community, there is a lot about osteoarthritis that we don’t understand,” Prof Anderson says.
“It is one of the most common degenerative joint diseases, yet there are limited diagnostic tools, few treatment options and no cure.”
Existing OA biomarkers are still largely focused on bodily fluids which are neither reliable nor sensitive enough to map all the changes in cartilage damage.
By understanding the biomolecular structure at the tissue level and how the joint tissues interact in the early stages of osteoarthritis, UniSA researchers say any molecular changes could be targeted to help slow the progression of the disease with appropriate medication or treatment.
Osteoarthritis affects an estimated 2.2 million Australians and more than 300 million people worldwide, with those aged over 45 most at risk. Being female, overweight, and having existing joint injuries increases the risk of getting OA.
In Australia, $3.75 million is spent on joint replacements alone for osteoarthritis patients each year, and other indirect costs related to lost work productivity and loss of wellbeing are estimated to be more than $23 billion a year.
In a recent paper published in the International Journal of Molecular Sciences, Lee and her colleagues from UniSA’s Musculoskeletal Biology Research Laboratory and the Future Industries Institute explore how advances in mass spectrometry imaging (MSI) to detect OA are promising.
“To date, diagnosing osteoarthritis has relied heavily on x-rays or MRI, but these provide limited information and don’t detect biomolecular changes that signal cartilage and bone abnormalities,” Lee says.
“By contrast, alternative imaging methods such as MSI can identify specific molecules and organic compounds in the tissue section.”
MSI has already demonstrated its strengths in identifying biomarkers for different types of cancer, and UniSA researchers are hopeful it can achieve the same for early diagnosis of osteoarthritis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Team links gait change after ACL injury and knee osteoarthritison January 14, 2021 at 6:54 am
A new study with mice links altered gait after surgery for an ACL injury with knee osteoarthritis for the first time.
- Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritison January 14, 2021 at 4:18 am
We are very pleased to have initiated our ReNu pivotal Phase 3 trial,” said Patrick Bilbo, Chief Operating Officer for Organogenesis. “This significant milestone comes on the heels of the FDA’s RMAT ...
- Spine Osteoarthritis Pain Drug Market Outlook 2021: Industry Analysis, Cost Structures, Demand, Supply Chain relationship and Forecast to 2026on January 13, 2021 at 7:52 am
Final Report will add the analysis of the impact of COVID-19 on this industry." The Global "Spine Osteoarthritis Pain ...
- Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Resultson January 13, 2021 at 4:28 am
Full-year 2020 net sales estimated to be approximately $85.5 million Company names Adam Muzikant, Ph.D., Chief Business Officer BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion ...
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For ...on January 12, 2021 at 1:43 am
RMAT Designation Enables Closer FDA Interactions to Support Accelerated Approval CANTON, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Orthofix Announces Participation in Upcoming J.P. Morgan Healthcare and ICR Westwicke Conferenceson January 7, 2021 at 4:19 am
Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will participate in two upcoming virtual investor ...
- Study Identifies Potential New Biomarkers of ILD in Rheumatoid Arthritison January 6, 2021 at 12:52 pm
Study findings, published in Frontiers in Medicine, underscore the importance of metabolic profiling for discovering candidate screening biomarkers for interstitial lung disease (ILD) in rheumatoid ...
- Landos Biopharma Announces Positive Results from a Phase 2 Trial of Oral BT-11 for Patients ...on January 5, 2021 at 2:42 am
Normalization of fecal calprotectin levels, commonly cited to be one of the most predictive biomarkers of response to treatment ... for the treatment of lupus nephritis, rheumatoid arthritis, multiple ...
- Begone 2020: Despite COVID, Alzheimer’s Research Advancedon January 4, 2021 at 8:52 am
By June, investigators had adjusted and research began to get mostly back on track (Jun news). Some clinical trials were abandoned (Jun news), but even so, as outlined in this yearly research roundup, ...
- Osteoarthritis Therapeutics Market, 2025 - ResearchAndMarkets.comon December 30, 2020 at 5:04 am
Osteoarthritis (OA ... Additionally, the development of imaging biomarkers based on radiographic features, coupled with the introduction of analgesic drugs, is contributing to the market growth.